As we move towards an era of precision medicine, the ability to predict patient-specific drug responses in cancer based on molecular information such as gene expression data represents both an opportunity and a challenge. In particular, methods are needed that can accommodate the high-dimensionality of data to learn interpretable models capturing drug response mechanisms, as well as providing robust predictions across datasets.
Introduction
Cancer is a genetic disease caused by the accumulation of mutations, ranging from point mutations to copy number variations and structural alterations. These, in turn, impact gene expression and ultimately contribute to the hallmarks of cancer, including uncontrolled cell proliferation and metastasis. Compared to commonly used cancer treatments such as chemotherapy or radiotherapy, targeted drugs can be better at killing tumor cells and/or have lesser toxicity to normal tissues (Begg et al., 2011) . However, not every patient responds to drug therapy in the same way, and molecular information such as mutation or gene expression data can inform us on which patients will respond to a drug. For example, KRAS mutations can be used as predictors of resistance to therapy with EGFR Inhibitors (Massarelli et al., 2007) , and targeting overexpressed Bcl-2, as observed in small-cell lung cancer, has been shown to provide therapeutic benefits (Gandhi et al., 2011) . These findings emphasize the need for using molecular information to predict drug response and thus personalize cancer therapy (Thangue and Kerr, 2011; Veer and Bernards, 2008) .
As the number of patients/tumors with molecular data increases across cancer types, enabled particularly by large-scale studies such as TCGA and ICGC (Weinstein et al., 2013; Zhang et al., 2011) , the identification of cancer driver genes has benefited greatly (Cerami et al., 2012; Zhang et al., 2011; Weinstein et al., 2013; Bertrand et al., 2017) . However, these data sources typically lack drug response information and are therefore not suitable for identifying drug response biomarkers. On the other hand, drug screening on several panels of cancer cell lines has been conducted, for example, in the Cancer Cell Line Encyclopedia (CCLE) and the collaborative Genomics of Drug Sensitivity in Cancer (GDSC) projects (Barretina et al., 2012; Iorio et al., 2016) . These cell line datasets allow us to utilize genomic features and apply mathematical and statistical approaches to decipher functional relationships and construct models that can predict patient-specific drug responses.
Several types of models have been proposed for predicting drug responses using genomic features (Azuaje, 2016; Costello et al., 2014; McLeod, 2013; Wheeler et al., 2012) . The most widely used type is a drugspecific model, which is independently trained for each drug based on genetic and drug response information from cell lines tested with each drug individually. Some of the methods that fall in this category include, a linear regression model using baseline gene expression (Barretina et al., 2012; Iorio et al., 2016; Geeleher et al., 2014) or based on a combination of gene expression and other genomic information such as copy number alterations and DNA methylation (Ding et al., 2016; Chen and Sun, 2016) , nonlinear models such as neural networks, random forests, support vector machines and kernel regression based on multiple types of genomic information (Cortés-Ciriano et al., 2016; Dong et al., 2015; Gupta et al., 2016) , and a neural network model that also incorporates drug property information (Menden et al., 2013) .
Drug-specific models are typically limited by the number of cell lines that have been tested with a given drug. To increase the number of data points and obtaining more robust and general models for drug response, a Bayesian multitask multiple kernel learning (BMTMKL) approach was proposed and exhibited the best performance in the DREAM challenge for drug response prediction (Costello et al., 2014) . This work highlighted the importance of sharing information across drugs in improving the accuracy of drug response prediction.
Multitask learning assigns all drugs equal importance in response prediction for a given drug, but it is likely more meaningful to construct a model that prioritizes information from similar drugs, as is possible using collaborative filtering techniques. In the area of recommender systems, collaborative filtering is a framework to analyze relationships between users (cell-lines/patients) and dependencies among items (drugs) to identify new user-item associations (patient-specific drug response) (Koren et al., 2009) . The two major classes of collaborative filtering techniques are (i) neighborhood methods, which predict the user-item association based on predefined user-user and item-item similarities, and (ii) latent factor models, which use matrix factorization to identify a latent space that captures user-item associations. Matrix factorization techniques, in particular, have shown promising results in the Netflix Prize, a competition for collaborative filtering methods to predict user ratings for movies based on a rating history (Bennett and Lanning, 2007) .
Collaborative filtering techniques have also been used for predicting patient-specific drug responses in a few studies. Based on a neighborhood approach, Sheng et al (Sheng et al., 2015) defined drug-specific cell line similarity and drug structural similarity, and then predicted unobserved drug responses by calculating a weighted average of observed drug responses according to both drug and cell line similarity. This model is purely based on the assumption that the predefined similarities can explain drug responses, but it did not take into account observed drug response information to define drug similarity. In contrast, using the latent factor approach, Khan et al (Khan et al., 2016) constructed component-wise kernelized Bayesian matrix factorization (cwKBMF) models to predict unobserved drug responses based on multiple cell line kernels and observed drug response data. Khan et al showed that cwKBMF can identify drugpathway associations and outperformed BMTMKL (Costello et al., 2014) in drug response prediction. However, a common limitation of both models is a need for normalization of drug response data, with this preprocessing step leading to a loss of information on relative ranking of drugs within each cell line. Overall, the availability of limited training data, with a small number of cell lines tested with each drug, represents a major challenge for learning robust models that provide meaningful predictions in new datasets. Additionally, the interpretability of models and their use to obtain biological insights has not been extensively explored in the field.
To address these limitations and to develop more robust models based on information sharing across multiple drugs, we developed the CaDRReS (for Cancer Drug Response prediction using a Recommender System) framework. CaDRReS maps drugs and cell lines into a latent "pharmacogenomic" space to predict drug responses for specific unseen cell lines and patients. Our benchmarking analysis using publicly available datasets (CCLE, GDSC) suggests that this allows CaDRReS to have notably better predictive performance and robustness than other existing methods. Comparisons on unseen patient-derived cell-line datasets also highlight CaDRReS's robustness and ability to generalize across datasets, an important requirement for precision oncology applications. Additionally, we show that the unique pharmacogenomic space model inferred by Ca-DRReS lends itself well to biological interpretation, allowing us to (i) understand drug response mechanisms, (ii) identify cellular subtypes from drug response profiles, and (iii) characterize drug-pathway associations.
Methods

Datasets and Data Preprocessing
Drug-screening data for cancer cell lines was obtained from two largescale studies, CCLE and GDSC, and all cell lines with baseline gene expression data were retained. A Bayesian sigmoid curve fitting approach was applied to raw intensity data at different drug dosages to recompute #$ (minimal concentration that induces 50% cell death) values that were more comparable across datasets (see Supplementary method 1, Supplementary figure 1 and Supplementary tables 1-2 for details). Drugs with median #$ less than 1 µM tend to be cytotoxic drugs with high toxicity across cell lines and were therefore excluded (Supplementary figure 2) . Our final dataset contained 491 cell lines, 19 drugs, and 9,096 experiments from CCLE, and 983 cell lines, 223 drugs, and 179,633 experiments from GDSC, providing a large dataset for training and validation of our models. Additionally, an in-house dataset based on screening of 276 drugs (65 of which overlap with GDSC) on 8 head and neck cancer (HNC) patientderived cell lines from 5 subjects was used (Chia et al., 2017) . Two of the cell lines were found to be not sensitive to any of the overlapping drugs (inhibition score <50 at 1 ), while one was found to be sensitive to more than 25% of the overlapping drugs. Excluding these, 325 data points from 5 cell lines were used as an independent dataset to evaluate predictions from different models.
Cancer Drug Response prediction using a Recommender System
The first step in CaDRReS is to calculate cell line features based on gene expression information. To do this, we normalized baseline gene expression values for each gene by computing fold-changes compared to the median value across cell lines. For the next step, since the drug response experiments in GDSC and CCLE aim to measure cell death, 1,856 essential genes identified based on large-scale CRISPR experiments (Wang et al., 2015) were selected to condense the expression information for each cell line. Pearson's correlation for every pair of cell lines was calculated using the expression fold-changes of these essential genes. Thus, in total, we had 491 and 983 cell line features for CCLE and GDSC, respectively. For training the model, a drug sensitivity score = −log ( #$ ) was defined where the higher the score the more sensitive the cell line is to the drug. Models were trained and tested independently for CCLE and GDSC to avoid biases towards either of the datasets (Haibe-Kains et al., 2013; Haverty et al., 2016) .
To train CaDRReS, we used matrix factorization to learn a 'pharmacogenomic space' i.e. a latent space to project drug and cell line data such that the dot product between a cell line vector and a drug vector provides the cell-line specific drug response (Figure 1A) . Drug sensitivity models were then computed based on equation 1: s 12 = µμ + 6 7 + 8 9 + 2 ⋅ 1 = µμ + 6 7 + 8 9 + 2 1 9 ?
(1) where 86 is the predicted sensitivity score of cell line to drug , is the overall mean drug response, 6 7 and 8 9 are bias terms for drug and cell line , respectively, 6 , 8 ∈ ℝ E are vectors for drug and cell line in the -dimensional latent space and G ∈ ℝ H ×E is a transformation matrix that projects cell line features 8 ∈ ℝ H onto the latent space. The value of was set at 10 for both CCLE and GDSC datasets based on cross validation performance. As shown in Figure 1A , this can be depicted as drug response matrix ( ) being factorized into biases ( ) and matrices of cell lines ( ) and drugs ( ). Rows of the cell line matrix ( ) and the drug matrix ( ) are vectors of cell lines and drugs in a latent space, respectively.
CaDRReS
The latent pharmacogenomic space captures interactions between drugs and the genomic background of cell lines such that the dot product between a cell line vector and a drug vector ( ⋅ ) represents the interaction between the drug and the cell line. As shown in Figure 1B (center), cell line is sensitive to drug and drug while not being sensitive to drug . Similarly, cell line is unlike cell line and does not respond to drugs and . This representation thus has many applications including (i) predicting drug responses of unseen samples (cell lines or patients), (ii) revealing drug mechanisms and (iii) subtypes of cell lines, and (iv) identifying drugpathway associations (Figure 1B) as will be discussed in later sections.
In order to train the model the following 'sum of squared error' loss function was optimized: where 86 and 86 are observed and predicted sensitivity scores for cell line using drug , respectively, = { 6 , 8 , G , 6 }, and | | is the number of drug response experiments in the training dataset. Finally, we applied gradient descent to optimize this loss function and obtain all parameters in (see Supplementary method 2). We tested CaDRReS' robustness by constructing 10 different models from different random starting points for the gradient descent optimization and observed that the models show similar performance (Supplementary figure 3 ).
Comparisons with Related Methods
We compared the predictive performance and robustness of CaDRReS against other existing methods including a method based on the elastic net regression model (ElasticNet; Barretina et al., 2012; Iorio et al., 2016) , cwKBMF (Khan et al., 2016) , the method from Sheng et al (Sheng et al., 2015) , as well as a control method based on random permutations of the drug sensitivity scores for each cell line (Control) . For ElasticNet, the model was trained for each drug as described previously (Barretina et al., 2012; Iorio et al., 2016) using the Elastic Net library from Scikit-learn ( 1ratio = 0.5; Pedregosa et al., 2011) , where the model automatically selects the genes. For the method proposed by Sheng et al (Sheng et al., 2015) , we re-implemented it as described in the paper, normalized drug response data, calculated drug similarity and drug-specific cell line similarity scores and set the parameters H (number of similar drugs) = 3 and ` (number of similar cell lines) = 9 as used in the paper. For cwKBMF, drug response data was normalized for each drug as described in the paper and the provided MATLAB source code was used to train a model.
Evaluation Metrics
We performed 5-fold cross-validation to evaluate the predictive performance of the models. For evaluating cell line ranking for each drug, we calculated Spearman correlation ( a ) and reported the average correlation across drugs. To evaluate models for each cell line, the normalized discounted cumulative gain (NDCG), a widely used score for evaluating ranking recommendations, was calculated as follows:
where is the predicted rank of drugs tested on a cell line, is a list of observed drug sensitivity scores and is the known ranking of drugs. NDCG ranges from 0 to 1, where 1 indicates that the model correctly predicts the ranking of drugs. The numerator in DCG is designed to give greater weight to a drug with higher sensitivity score, while the denominator gives preference to drugs predicted to have higher ranks. 
Identifying Drug-Pathway Associations
Using 217 Biocarta pathway gene sets from MSigDB (Liberzon et al., 2011) , pathway activity scores were calculated for each cell line by summing up gene expression fold-changes of genes in each pathway. To identify drug-pathway associations, we then calculated the Pearson correlation between pathway activity scores and predicted drug responses ( ( ); lower values indicate greater response), where a negative correlation suggests that a pathway is essential for drug effectiveness, while a positive correlation suggests that it plays a role in drug resistance.
Results
Performance and Robustness of CaDRReS
A common way to evaluate drug response prediction methods is to assess their correlation (or squared error) compared to known responses for each drug (across cell lines) in a cross-validation framework (Barretina et al., 2012; Iorio et al., 2016) . Using the matrix-factorization based approaches, CaDRReS and cwKBMF showed significantly better performance than ElasticNet, Sheng et al, as well as the Control method (p-values <10 -30 ) in both the CCLE and GDSC datasets (Figure 2A) . While the ability to predict cell line responses for a given drug is useful to understand drug efficacy and to characterize drug mechanisms, ranking drugs for a given unseen cell-line/patient may be more relevant for precision oncology applications. Based on a weighted scoring of rankings (NDCG), we noted that CaDRReS and ElasticNet exhibited similar performance and improved notably over cwKBMF, Sheng et al, ; Figure 2B) . Taken together, these results suggest that CaDRReS improves over existing approaches in providing models that are useful for both drug response prediction across cell-lines and within a cell-line. For drug response prediction within a cell-line, although ElasticNet models were trained independently for each drug, their NDCG scores were surprisingly high. We suspected that this may be due to overfitting while training using a limited number of cell lines for each drug. To assess this, we evaluated the robustness of ElasticNet models learned across crossvalidation runs and found that <10% of the selected genes were shared across folds and half of the genes were selected in only one fold ( Figure  2C) . In contrast, CaDRReS showed consistently high correlation for drug biases (0.99; Figure 2D ) and cosine similarity of inferred drug vectors (0.96) across cross-validation runs, as well as high correlation for cell line biases (0.96; Figure 2E ) and cosine similarity of the inferred cell line vectors (0.88), highlighting the robustness of its models.
To further evaluate their performance, CaDRReS and ElasticNet models were trained on the GDSC dataset and tested on an independent dataset from patient-derived HNC cell-lines. Sheng et al and cwKBMF were not included here because they require normalization of drug response data, which leads to a loss of drug ranking information within a cell line. Despite having similar performance on the GDSC dataset, CaDRReS outperformed ElasticNet on this independent dataset (Figure 2F) , emphasizing its ability to provide more robust and generalizable models. In particular, CaDRReS was able to identify on average at least one drug that elicited a strong response for each cell-line among its top 3 predictions, while a baseline method based on average response across cell lines identified none.
Investigating Drug Mechanisms via the Pharmacogenomic Space
We trained CaDRReS models on the full datasets to obtain drug and cellline biases, as well as the pharmacogenomic spaces capturing drug-drug, cell line-cell line, and drug-cell line associations for both CCLE and GDSC (Supplementary figure 4) . Then to study drug mechanisms, we took vectors defined for each drug in the pharmacogenomic space, computed cosine similarities between every pair, and compared these to a commonly used drug structural similarity score (Tanimoto coefficient of SMILES calculated using the SMSD toolkit; Rahman et al., 2009) . Drug relation of the observed drug responses (0.51 with p-value < 10 -29 ). This is likely due to the fact that PD-0332991 is a CDK4/6 inhibitor that can reduce RB phosphorylation (Fry et al., 2004) , while PHA-665752 can inhibit c-MET and thus result in reduced phosphorylation of RB downstream (Ma et al., 2007) . Thus drug similarity in the pharmacogenomic space has the potential to capture deeper similarities in drug response mechanisms beyond those observed purely based on drug structural similarity.
In the pharmacogenomic space, we observed that clusters of drugs frequently represent groups that target the same gene or pathway (Figure 3A,  Supplementary figure 6) . For example, EGFR inhibitors (Lapatinib, ZD-6474, AZD0530, Erlotinib), RAF inhibitors (RAF265, PLX4720) and MEK inhibitors (PD-0325901, AZD6244) in CCLE formed separate clusters based on cosine similarity. In addition, cosine similarities among the five MEK1 inhibitors in GDSC (CI-1040, PD-0325901, RDEA119, Trametinib, and selumetinib) were significantly higher than between MEK1 inhibitors and other drugs (p-value <10 tu# ). A similar trend was also observed for the four BRAF inhibitors, AZ628, Dabrafenib, PLX4720, and SB590885 (p-value <10 tv ; Figure 3B) . These observations are interesting given that CaDRReS was trained based solely on drug response data, without any other information on drug properties.
By examining dimensions of the pharmacogenomic space, we observed that each dimension captured different aspects of sensitivity to various drug classes (Figure 3C) . For example, EGFR inhibitors dominated in the 5th and 9th dimensions and thus cell lines that were projected close to the positive sides of these dimensions have higher EGFR inhibitor sensitivity. Additionally, we observed that MEK inhibitors lie on the negative side of the 8 th dimension and the values of cell line vectors in this dimension were most positively correlated with activity scores for the EIF2 pathway (0.217), indicating that cell-lines with inactivated EIF2 pathway may be more sensitive to MEK inhibitors. This observation is in agreement with prior work showing that MEK inhibitors work by inducing activation of eIF-2B, which results in a shutdown of cellular protein synthesis and leads to apoptosis (Quevedo et al., 2000; Liberzon et al., 2011) . These results highlight the utility of the pharmacogenomic space learned by CaDRReS for capturing interpretable information related to drug mechanisms and pathways.
Cell Line Subtypes in the Pharmacogenomic Space
Clusters of cell-lines in the pharmacogenomic space should in-principle be tuned to capture drug-response similarities. However, not surprisingly we found that they also capture tissue type signatures, with cell-lines from the same tissue type showing significantly higher cosine similarity than cell-lines from different tissue types (Figure 4A, Supplementary figure  7A) , and also being visually distinct in t-SNE (Maaten and Hinton, 2008) 2D space (Figure 4B, Supplementary figure 7B) . Further segregation into histological subtypes was not always as clear (Supplementary figure  7C) , though most small cell lung carcinoma (SCLC) cell-lines were distinct from non-small cell lung carcinoma (NSCLC) cell-lines (except for NSCLC carcinoid cell-lines; Figure 4C) . The placement of NSCLC carcinoid cell-lines with SCLC cell-lines is clearly reflected in their drugresponse profiles: e.g. while NSCLC cell-lines were typically sensitive to PD-0325901 (MEK inhibitor), carcinoid cell-lines were not (Supplementary figure 8 ). In addition, we found that cell-lines with KRAS mutations had significantly higher predicted PD-0325901 sensitivity (adjusted pvalue <1.4×10 tx ), and that KRAS mutations were common in NSCLC cell lines (~30%) but not seen often in SCLC or carcinoid cell-lines (~3%), in agreement with prior work on KRAS mutations being activation biomarkers for MEK inhibitors (Stinchcombe and Johnson, 2014) .
By leveraging pathway information, we observed that activity scores for the ERK pathway in NSCLC cell-lines (mean=1.52) were significantly higher than for SCLC cell-lines (mean=-3.24; p-value <1.3×10 ty ), and the activation of ERK pathway due to KRAS mutation could play a role in the increased sensitivity to MEK inhibitors (RAF-MEK-ERK pathway; Stinchcombe and Johnson, 2014) . In contrast, cell-lines with RB1 mutations had a significantly lower PD-0325901 sensitivity (adjusted p-value <7×10 tx ), and correspondingly RB1 mutations were more common in SCLC cell-lines (67%) than in NSCLC cell-lines (10%). These observations corroborate earlier work suggesting that mutations in the RB1 pathway can inhibit the RAF-MEK-ERK pathway and thus induce resistance to MEK inhibitors (El-Naggar et al., 2009) . Cell-line clusters determined by CaDRReS thus correlated well with mutation and pathway activation in explaining drug responses, and could serve to construct new testable hypotheses when such information is not known.
Associations between Drugs and Pathways
Associations between cancer drugs and key pathways can be identified in the pharmacogenomic space based on pathway activity scores, cell line vectors, and drug vectors (see Methods and Supplementary tables 3, 4) . As expected, we observed that drugs targeting the same gene were frequently associated with the same set of pathways ( Figure 5A) . For instance, four EGFR inhibitors had IC50 values that were negatively correlated with activation scores for the EGFR SMRTE pathway (assistant association), consistent with a study showing that amplification of the EGFR gene is correlated with high response to anti-EGFR agents. (Normanno et al., 2006) . Similarly, two RAF inhibitors showed assistant associations with the VEGF-Hypoxia-Angiogenesis pathway (VEGF), in agreement with previous studies showing that VEGF expression induced by Raf promotes angiogenesis, while RAF inhibitors can block the RAF/MEK/ERK pathway and inhibit tumor angiogenesis (McCubrey et al., 2007; Liu et al., 2006) . We also observed resistant associations between the MTA3 pathway (MTA3) and multiple drugs such as L-685458 (gamma-secretase inhibitor) and PD-0332991 (CDK4/6 inhibitor), suggesting that the cell lines with inactivated MTA3 pathway tend to be sensitive to these drugs. In addition, the study of Fujita et al. showed that the absence of MTA3 leads to invasive growth in breast cancer (Fujita et al., 2003) . Taken together, these observations suggest that drugs having resistant association with MTA3 pathway might be effective when tumor growth is caused by the downregulation of the MTA3 pathway, although further work is needed to confirm this hypothesis.
In terms of drug-pathway associations, we noted that the strongest assistant association was observed between the drug L-685458 (gamma-secretase inhibitor) and the IGF-1 MTOR pathway (Figure 5B) . This observation is also borne out in studies reporting that gamma-secretase inhibitors can inactivate MTOR signaling pathway and consequently induce apoptosis (Shih and Wang, 2007) . Interestingly, we observed a stronger association signal for predicted drug responses than observed drug responses, suggesting that CaDRReS may have an ability to reduce the noise observed in experimental drug response data. Stronger signals based on predicted drug responses were also observed for other known assistant associations, such as the one between Lapatinib (an EGFR inhibitor) and the EGFR SMRTE pathway (R=-0.440 vs -0.329) as well as the HER2 pathway (R=-0.288 vs -0.242) (Figure 5C ; Harari, 2004; Medina and Goodin, 2008) . These results highlight the utility of predictions from CaDDReS for discovering pathway biomarkers for drug sensitivity.
Discussion
Several drug response prediction models have been proposed in the literature, with a primary focus on predicting the response of different celllines to a given drug. Correspondingly, the performance of these models was evaluated for each drug individually based on the correlation between the predicted and observed drug responses. However, while predicting cell-line response to each drug may provide insights into differential drug response mechanisms, the ability to rank drugs for unseen cell-lines/patients is likely to be more useful from a clinical perspective. Therefore in this work, besides evaluating response correlations for each drug, we evaluated the ability to correctly order drugs for a given cell-line using a popular weighted metric for rankings (NDCG) . Under both these metrics of evaluation, CaDRReS consistently provided the best models and was also able to perform well on unseen datasets.
In addition to its robust models, a useful feature of CaDRReS is the ease with which its models can be interpreted, an aspect that has not been given the attention it deserves in earlier studies. Models trained by CaDRReS provide a projection of cell-lines and drugs into a pharmacogenomic space which can be used to explore drug-drug, cell line-cell line, and drug-cell line relationships as shown in sections 3.2-3.4. This is in addition to the easy visualization and clustering analysis that this representation permits (e.g. Figure 3 or Figure 4) . In contrast, while the ElasticNet model provides high concordance between observed and predicted cell line rankings, non-robustness in gene selection means that it may not be meaningful to biologically interpret the selected set of genes for a given drug. Similarly, while the cwKBMF model incorporates pathway information and can be used to infer the strength of drug-pathway associations, it does not provide directionality for these associations. CaDRReS models start off by being agnostic of pathways but by incorporating this information later, allow us to identify both strength and directionality of drug-pathway associations as highlighted in the results in Figure 5 .
Currently, drug response prediction models are trained on drug response data for cancer cell lines, but ignore the toxicity of drugs due to the unavailability of corresponding information using normal cells. This likely limits the practical utility of such models as drugs that elicit a strong response across cell lines may also have higher toxicity. Refined models that take into account drug toxicity could also find application in studying drug synergies using the pharmacogenomic space: the sum of drug vectors could be used to predict synergistic response, and thus enable the goal of reducing drug dosage to limit side-effects.
An important limitation for the field of drug sensitivity prediction is that despite the presence of several publicly available cancer drug-screening datasets, the number of cell types and drugs in each dataset is still limited compared to the complexity of the models. Being able to merge information across multiple datasets could thus help construct more robust and general models. Experimental inconsistencies and noise across datasets have so far, however, stymied efforts to work towards this goal (Haibe-Kains et al., 2013; Haverty et al., 2016) .
Although CaDRReS was among the top performing models for both cell-line and drug ordering in Figure 2 , it still considered only gene expression of essential genes in its models. We suspect that integrating other types of omics data, such as mutations, in a meaningful manner can enrich information in the dataset and thus improve the predictive performance of corresponding models. Additionally, using information from gene interaction networks to capture relationships between genes could be another way to improve the performance and interpretability of this model in the future.
